Latest Gilead Sciences Stories
HONG KONG, Feb. 4, 2013 /PRNewswire/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and equity research for the following companies: National-Oilwell Varco (NYSE:NOV), Gilead Sciences (NASDAQ:GILD), Dow Chemical (NYSE:DOW), Chesapeake Energy (NYSE:CHK), Barrick Gold (NYSE:ABX), and ConocoPhillips (NYSE:COP). (Logo: http://photos.prnewswire.com/prnh/20130130/HK50859LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...
MISSISSAUGA, ON, Jan. 31, 2013 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) (the "Company" or "YM") is pleased to announce that, at the special meeting (the "Meeting") of shareholders of the Company (the "YM Shareholders") held earlier today, the YM Shareholders approved the previously announced plan of arrangement (the "Arrangement") involving the Company, Gilead Sciences, Inc. ("Gilead") and 3268218 Nova Scotia Limited, a wholly-owned subsidiary of Gilead (the...
LONDON, January 30, 2013 /PRNewswire/ -- EmergingGrowth.com, a leading digital financial media company, discusses Sunesis Pharmaceuticals, Amgen, Inc., Gilead Sciences and Biogen Idec, Inc. The pharmaceutical sector is a very lucrative and competitive industry. And for emerging growth companies, it is difficult to make a meaningful impact in this cutthroat industry. Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) has built a highly experienced cancer drug...
Lee Rannals for redOrbit.com – Your Universe Online Replacing brand-name, antiretroviral drugs recommended for control of HIV infection with generic medications could save nearly $1 billion a year on health care costs in the US. This strategy of replacing the brand-name drugs with the soon-to-be-available generic drugs could also come with its risks, diminishing the efficacy of the HIV treatment. "The switch from branded to generic antiretrovirals would place us in the...
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB001-A, the company's anti-PcrV Humaneered®, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously administered KB001-A as a treatment for chronic Pseudomonas aeruginosa (Pa) infection in cystic fibrosis patients. The Phase 2...
ROCKVILLE, Md. , Jan. 7, 2013 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced it has entered into a license agreement with Gilead Sciences, Inc. (Nasdaq: GILD) for the development and commercialization of Dual-Affinity Re-Targeting (DART(TM)) products directed at up to four undisclosed targets. MacroGenics' DART technology is a...
- Adds Selective JAK Inhibitor to Growing Oncology and Inflammation Pipeline - FOSTER CITY, CA AND MISSISSAUGA, ON, Dec. 12, 2012 /PRNewswire/ - Gilead Sciences, Inc. (Nasdaq: GILD) and YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM's Board of Directors, and values YM at approximately...
TITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT(®) for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults....
New research report “KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen” elaborated by FirstWord has been recently published by Market Publishers Ltd. The study says that the HCV market is expected to have the best growth opportunities over the coming decade in comparison with other Pharma markets. London, UK (PRWEB) November 30, 2012 At present, the hepatitis C (HCV) market is entering a new stage due to the emergence of treatment innovations. The HCV market is...
VANCOUVER, British Columbia, Nov. 21, 2012 /PRNewswire/ -- EarningForecast.com has issued consensus earnings forecast reports and equity research for the following companies: Intel (NASDAQ:INTC), Lowe's (NYSE:LOW), Groupon (NASDAQ:GRPN), Chesapeake Energy (NYSE:CHK), Teavana (NYSE:TEA), and Gilead Sciences (NASDAQ:GILD). (Logo: http://photos.prnewswire.com/prnh/20121030/HK02457LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to...
